Several 4-quinolone antibacterials (norfloxacin HCI, enoxacin, ofloxacin, cinoxacin, ciprofloxacin, and nalidixic acid) were administered intradermally to male and female hairless guinea pigs (Crl:IAF(HA)BR). Immediately prior to the intradermal injection, the guinea pigs were given an intravenous injection of Evans blue dye. The diameter of the blue spots at the sites of intradermal injection 15 to 30 minutes after intradermal injection were used as a measure of cutaneous anaphylactoid activity. The quinolones were given in concentrations ranging from 0.009 to 4.0 mg/mL. Compound 48/80 was used as a positive control, and saline was used as the negative control. All the 4-quinolones tested, except nalidixic acid, were positive for cutaneous anaphylactoid activity. Norfloxacin, enoxacin, and ciprofloxacin were positive at concentrations of 0.13 mg/mL or higher. Ofloxacin and cinoxacin were positive at concentrations of 2.0 mg/mL or higher. Pretreatment with the HI blocker, chlorpheniramine maleate, resulted in diminished responses. These results demonstrate the potential for adverse cutaneous anaphylactoid reactions, presumably due to release of vasoactive mediators, with 4-quinolone antibacterials, and illustrate a simple method to screen new compounds for this activity.
INTRODUCTION he 4-quinolones are a class of antibacterials that has proved useful in a variety of urinary, respiratory, and T gastrointestinal tract, skin, bone, and joint infections. They are primarily effective against gram-negative and gram-positive aerobic bacteria and are particularly useful against infections resistant to other classes of antibiotics"'. They are the first oral agents effective against Pseudomoms and other resistant gram-negative bacteria.
With the widespread clinical use of 4-quinolones, reports have appeared of occasional rashes (erythema and/or PNritiS) and, in some cases, anaphylactoid reactions in patients given certain of these compounds'2-'0'. This appears to occur most frequently when administration is by the parenteral route. This prompted us to try to determine if 4-quinolone antibiotics might have a tendency to cause histamine release.
Since the clinical side effect of interest in this study was cutaneous, a cutaneous anaphylaxis-type model was considered most appropriate to hopefully predict the clinical response. We chose to modify the guinea pig cutaneous anaphylaxis model that quantitates changes in local vascular permeability because this method is simple to conduct, sensitive, reliable, has been used previously for testing histamine-releasing agents" ') and has been used previously in our laboratory. Crl:IAF(HA)BR hairless guinea pigs were used since the use of hairless guinea pigs eliminates the necessity for shaving and facilitates the assessment of positive responses. We have previously found hairless guinea pigs to be equally sensitive to positive control compounds as Hartley strain guinea pigs in both passive cutaneous anaphylaxis and delayed hypersensitivity reactions.
METHODS
The Crl:IAF(HA)BR hairless guinea pigs weighed about 400 g upon arrival from Charles River Lakeview, Newfield, NJ. The guinea pigs were assigned to treatment groups after acclimation to the laboratory for 7 days. The guinea pigs were housed individually in stainless steel cages. Food (Certified Guinea Pig Chow #5026, Purina Mills, Inc., St. Louis, MO) and tap water were provided ad libitum. Ambient temperature was maintained at 74 +/-/5"C. The animal room was on a 14-hour daily light cycle. At the end of the study, the guinea pigs were euthanized with carbon dioxide and discarded. The study design was approved by the Institutional Animal Care and Use Committee.
For the first experiment, each guinea pig was given an intravenous injection (1 .O d a n h a l ) of 0.5% Evans blue dye in 0.9% sodium chloride for injection, USP, via a foreleg vein. Immediately following the intravenous injection, each guinea pig received intradermal injections (0.1 &test site) of test materials. Each of the 6 guinea pigs (3 females and 3 males) in a given group received 8 intradermal injections, 1 each for saline (negative control), compound 48/80 (positive control), and the 6 quinolones tested. The quinolones were tested at concentrations of 0.009,O. 13, 2.0, and 4.0 mglmL. The intradermal injections were placed about 1.5 cm from the midline of the back and between the shoulders and base of the sacrum. The injections were spaced at least 3 cm apart and were on alternating sides of the midline. The location of the injection sites for individual test materials was randomized so that each of the test materials was injected in a different location for each of the 6 guinea pigs in a given group. The injections were given with 25 gauge needles.
About 15 to 30 minutes after the intradermal injections, the injection sites were examined for the presence of a blue spot. The diameters of the blue spots on the back of each guinea pig were measured as an indication of the relative increase in vascular permeability. Measurements were made with a flexible ruler laid across the back of the guinea pig. The blue spots were generally oval in shape. The largest diameter was taken as the measurement for a given spot.
The second experiment was conducted exactly as the first, except that the guinea pigs (6 males per group) received 6 mg chlorpheniramine maleate intravenously 1 to 2 hours prior to intradermal injection of test material. This dose was selected because it is in the range of the dose for a single injection in clinical use, and because on a mgkg basis it provided a large excess (over 50 times) over that known to be pharmacologically effective Formulations of all test materials were made using 0.9% sodium chloride for injection, USP. Statistical analysis of the response diameters consisted of analysis of variance followed by Duncan's multiple comparison test. All statistical analyses were conducted at thep = 0.05 level of significance. Since there was no apparent difference in responses between males and females, the results for both sexes were pooled within treatment goups. For each data point, N = 6. For the first experiment, the results for the 6 quinolones at a given concentration were compared simultaneously to each other and to concurrent positive and negative control results. This was repeated for each of the 4 concentrations used. For the second experiment, results for all concentrations of a given test material with and without chlorpheniramine pretreatment were compared simultaneously by analysis of variance followed by Duncan's multiple comparison test.
Sodium chloride for injection, USP, and norfloxacin were obtained from Abbott Laboratories, North Chicago, IL. Compound 48/80, chlorpheniramine maleate, and nalidixic acid were obtained from Sigma Chemical Co., St. Louis, MO. Enoxacin, ofloxacin, and ciprofloxacin were obtained as a gift from Tanabe Seiyaku, Osaka, Japan.
Cinoxacin was obtained from Eli Lilly and Co., Indianapolis, IN.
RESULTS AND DISCUSSION
All the 4-quinolones tested, except nalidixic acid, produced dose-related increases in cutaneous anaphylactoid responses as measured by the diameters of the blue spots (Table 1) . Greater responses were observed with noffloxacin, ofloxacin, and ciprofloxacin than with enoxacin or cinoxacin. Statistically significant positive results, compared to those with saline as a concurrent control, were obtained at concentrations of 0.13 mg/mL or higher with norfloxacin, enoxacin, and ciprofloxacin and at concentrations of 2 m@mL or higher with ofloxacin and cinoxacin. the other quinolones tested are the substitutions at positions 6 and 7, which are present in all the quinolones tested, except nalidixic acid. Also, nalidixic acid and cinoxacin, the least active of the compounds tested, are not fluorinated.
Pretreatment with chorpheniramine maleate (Table 2 ) caused a reduction in size of the responses observed with the quinolones as well as the saline control. However, the responses with the quinolones after clorpheniramine pretreatment were consistently statistically significantly lower than without chlorpheniramine pretreatment, whereas the response with saline was significantly lower in only 1 chlorpheniramine pretreated group, compared to the corresponding nonpretreated group. Since chlorpheniramine is a specific H1 receptor antagonist"2', this indicates histamine release was at least partially responsible for the results seen in this study and may be involved in the clinical manifestations mentioned previously.
Although some of the compounds used were likely to be acidic, preliminary studies showed the absence of blue spots when saline adjusted to pH 3.8 with HCl or to pH 10.4 when NaOH was used for intradermal injections.
The results of this study do not allow any distinction between secretory release of histamine from mast cells or cytotoxic release. In secretory release, which is the normal physiologic mechanism, the mast cell pengranule membrane fuses with the cell membrane, thus releasing histamine to the surrounding medium, whereas in cytotoxic release, histamine escapes the mast cell due to loss of membrane integrity"3'. At present there is insufficient data available on cytotoxicity with quinolone antibacterials to correlate the results reported here with cytotoxicity. Distinguishing between these two basic alternative mechanisms could be helpful for designing new compounds with reduced anaphylactoid activity. In addition, the involvement of other inflammatory mediators has not been ruled out and deserves further study.
The positive responses seen in the model used here provide a practical means to screen new 4-quinolones for the potential to cause cutaneous anaphylactoid activity, to thus hopefully minimize the side effects mentioned previously after parenteral administration.
